Radient Pharmaceuticals has registered patent applications for its non-invasive cancer blood test, Onko-Sure, in China and Japan.

Onko-Sure is a 96-well Enzyme-linked immunosorbent assay (ELISA) test kits used to detect and treat 19 different types of cancers.

Radient Pharmaceuticals chairman and CEO Douglas MacLellan said Japan and China are larger markets, where having patent protection improves their ability to forge productive distribution partnerships for their cancer test.